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Two novel cobalt(III) pyridine complexes (1) [Co(en)2(py)2]
3+ and (2) [Co(en)2(mepy)2]
3+ (en=ethylenediamine, py=pyridine,
and mepy=methylpyridine) have been synthesized and characterized. The interaction of these complexes with calf thymus DNA
was investigated by absorption, emission spectroscopy, viscosity measurements, DNA melting, and DNA photocleavage. Results
suggest that the two complexes bind to DNA via groove mode and complex 2 binds more strongly to CT DNA than complex 1.
Moreover, these Co(III) complexes have been found to promote the photocleavage of plasmid DNA pBR322 under irradiation at
365nm, cytotoxicity results of complexes are also showing anticancer activity.
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1. INTRODUCTION
The interaction of transition metal polypyridyl complexes
with DNA has received a great deal of attention during the
past decade [1–3]. Many complexes have been synthesized.
These complexes can bind to DNA in noncovalent modes
such as electrostatic, intercalative, and groove binding [4, 5].
Thecationicmetalcomplexespossessingplanararomaticlig-
andsmaybindtoDNAbyintercalationwhichinvolvesstack-
ing of the planar ligand in between adjacent base pairs of
the DNA duplex [6–9]. In the early 1980s, Barton demon-
strated that tris phenanthroline complexes of ruthenium (II)
display enantiomeric selectivity in binding to DNA, which
can be served as spectroscopic probes in solution to distin-
guish right- and left-handed DNA, helices [10]. Then they
found that tris (phenanthroline) complexes of cobalt(III)
could cleave DNA when irradiated at 254nm. Furthermore,
they conducted the cleavage reactions by using high stereo
speciﬁcity of tris (diphenyl penanthroline) (DIP) metal iso-
mers.Thecleavagereactionisalsostereospeciﬁc.Theseﬁnd-
ings underscore the importance of an intimate association
of the metal ion with the duplex. The high level of recog-
nition of DNA conformation by these chiral inorganic com-
plexessuggestedthepowerfulapplicationofstereospeciﬁcity
in DNA drug design [11]. According to [12], cis-a n dtrans-
[PtCl2(pyridine)2] complexes show anticancer activity and
inhibit DNA synthesis, implying a role for DNA binding in
their mechanism of action, and cis complex implies more
binding with CT DNA than trans complex.
A series of dichloro(ethylenediamine)-type platinum
complexes bearing ester-, amide-, and ether-bonded alkyl
straight chains were prepared as a model for the pro-
drug of cis-diamminedichloroplatinum [13] and the cy-
totoxic activity of the complexes against the S-180 cell
line was investigated. Schonenberger et al. presented anti-
tumor active (1,2-diphenylethylenediamine)-platinum (II)
complex compounds [14]. Ring-substituted diaqua(1,2-
diphenylethylenediamine) platinum(II) sulfate was pre-
pared [15] and mode of binding to the DNA was stud-
ied. A series of isomeric[1,2-bis (diﬂuorophenyl) ethylene-
diamine] dichloroplatinum (II) complexes and cis-platin
were tested on the P388 leukemia and on the murine2 Metal-Based Drugs
mammary carcinoma for evaluating antineoplastic ac-
tivity against breast cancer in vivo [16]. The activity
of 1,2-bis(2,6-diﬂuoro-3-hydroxy-phenyl)ethylenediamine]
platinum(II) complexes against breast cancer was investi-
gated in [17].
Our group has synthesized some Ruthenium(II) and
Cobalt(III) ethylenediamine mixed-polypyridyl com-
plexes, which bind to DNA through an intercalative and
groove mode and promote cleavage of plasmid pBR 322
DNA [18–21]. Herein we chose to concentrate on the
cobalt(III)ethylenediamine complexes, because they have
same interesting characteristics of metallointercalation. In
this paper, we are reporting the synthesis and characteriza-
tion of the complexes 1 and 2 in which 2 possesses a greater
binding aﬃnity and their DNA-binding properties are
revealed by electronic absorption, emission spectra, viscosity
measurement, and DNA melting curve. The photochemical
DNA cleavage of the complexes is also demonstrated. These
studies are necessary for further comprehension of binding
of transition metal complexes to DNA. The cytotoxicity
studies of 1 and 2 complexes were discussed in this paper.
2. EXPERIMENTAL
Materials. All materials were purchased and used with-
out further puriﬁcation unless otherwise noted. Pyridine,
ethylenediamine,andCTDNAwerepurchasedfromAldrich.
All the experiments involving interaction of the complexes
with DNA were carried out in BPE buﬀer (5mM Tris-HCl,
50mM NaCl, pH 7.0). A solution of calf thymus DNA in
the buﬀer gave a ratio of UV absorbance at 260 and 280nm
of about 1.90 indicating that the DNA was suﬃciently free
of protein [22]. The DNA concentration per nucleotide was
determined by absorption spectroscopy using the molar ab-
sorption coeﬃcient (6600M−1cm−1) at 260nm [23].
3. SYNTHESIS OF COMPLEXES
3.1. [Co(en)2(py)2]3+
Am i x t u r eo fcis-[Co(en)2Cl2]Cl (1.43g) was prepared by
the procedure available in the literature (see [24]). Com-
plexes 1 and 2 were prepared by literature methods [25–
27] as follows. A mixture of trans-[Co(en)2Cl2]Cl {4.28g,
0.015 mol} and pyridine {2.7g, 0.015mol} t a k e ni nd i s -
tilled H2O( 2 0 c m 3) was heated at 100◦Cf o r3 0m i n u t e s .
A saturated NaBr solution was added to the cooled so-
lution, which was kept overnight. After ﬁltration to re-
move [Co(en)3]Br3,M e 2CO (200cm3) was added, result-
ing in precipitation of a mixture of [Co(en)2(py)2]Br3 and
[Co(en)(py)4]Br3. This was dissolved in H2O and the com-
plex [Co(en)2(py)2]Br3 was reprecipitated by addition of
EtOH. [Co(en)2(Mepy)2]Br3, (2) was prepared similarly us-
ing methylpyridine. UV/Vis: 361,470 and 618nm Isosbestic
points: 438 and 576nm IR: 1457 (C=C), 1578 (C=N),
469 (Co−N (en)), 578cm−1 (Co−N (L)). Formula: Co
N6H26C14Br3Anal. Calc. H 4.54, C 29.14, N 14.56 found: H
4.01, C 29.0, N 14.02. 1H-NMR (D2O), 3.1,(dd, 2CH2 (en)2,
2.55(m,2CH2(en)2,7.69 (d,2H),8.210 (d,2H),7.990(t,1H).
3.2. [Co(en)2(mepy)2]3+
UV/Vis: 312, 447 and 617nm, Isosbestic points: 449 and
578nm IR: 1448 (C=C), 1577 (C=N), 467 (Co−N (en)),
555cm−1 (Co−N (L)). Formula: Co N6H30C16Br3,A n a l .
Calc. H 5.00, C 31.76 N 13.89 found: H 4.8 C 30.56 N 12.18.
1H-NMR (D2O), 2.7,(dd, 2CH2 (en)2, 2.89(m, 2CH2(en)2,
7.412(d, 2H), 8.036(d,2H) 4.412(s, 3H).
3.3. Physicalmeasurements
UV-Visible spectra were recorded on Elico Bio-spectro-
photometer model BL198, emission spectra were recorded
on a Shimadzu Rf-2000 luminescence spectrometer at room
temperature. IR spectra were recorded, in KBr phase on
Perkin-Elmer FTIR-1605 spectrophotometer; 1H-NMR spec-
tra were measured on a Varian XL-300MHz spectrometer
with D2O as a solvent at room temperature and tetramethyl-
silane (TMS) as the internal standard, Microanalyses (C, H,
N) were carried out on a Perkin-Elmer 240 elemental ana-
lyzer.
For the absorption spectra titrations were carried out at
room temperature to determine the binding aﬃnity between
DNA and complex. Initially, 3000μL solutions of the blank
buﬀer and the cobalt complex sample (20μM) were placed
in the reference and sample cuvettes (1cm path length), re-
spectively, and then ﬁrst spectrum was recorded in the range
of 200–600nm. During the titration, aliquot (1–10μL) of
buﬀered DNA solution (concentration of ∼5t o1 0m Mi n
base pairs) was added to each cuvette to eliminate the ab-
sorbance of DNA itself, and the solutions were mixed for
∼5 minutes, the absorption spectra were recorded. The titra-
tion processes were repeated until there was no change in the
spectraindicatingthatbindingsaturationhadbeenachieved.
The changes in the metal complex concentration due to di-
lution at the end of each titration were negligible. The cobalt
(III) complexes on other hand, showed additional MLCT
bands between 400–500nm [28].
Emission measurements were carried out by using a Hi-
tachiF 4500 Fluorescence Spectrometer. Tris-buﬀer was used
as a blank to make preliminary adjustments. The excitation
wavelength was ﬁxed and the emission range was adjusted
before measurements. All measurements were made at 25◦
in a thermostated cuvette holder with 5nm entrance slit
and 5nm exit slit. Emission titration experiments were per-
formed at a ﬁxed metal complex concentration (20μM) to
which increments of a stock DNA solution (0–160μM) con-
taining the same concentration of the metal complexes were
added. The emission enhancement factors were measured by
comparing the intensities at 559nm in the absence and pres-
ence of CT DNA.
Viscosity experiments were carried out using an Ostwald
viscometer maintained at a constant temperature 30.0±0.1◦
in a thermostatic water bath. Calf thymus DNA samples, ap-
proximately 200 base pairs in average length, were prepared
by sonicating in order to minimize complexities arising from
DNA ﬂexibility [29]. Data were presented as (η/η0)
1/3 versus
theconcentrationofCo(III)complexes,whereηistheviscos-
ity of DNA in presence of complexes and η0 is the viscosityPenumaka Nagababu et al. 3
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Figure 1: Molecular structure of complexes.
of DNA alone. Viscosity values were calculated from the ob-
served ﬂow time of DNA-containing solution (t>100 sec-
onds) corrected for ﬂow time of buﬀer alone (t0), η = t − t0
[30] .T h eD N Am e l t i n ge x p e r i m e n t sw e r ed o n eb yc o n t r o l -
ling the temperature of the sample cell with a Shimadzu cir-
culating bath while monitoring the absorbance at 260nm.
Thermal denaturation studies were carried out with a
Elico Bio-spectrophotometer model BL198, equipped with
temperature-controlling programmer (±0.1◦C). The ab-
sorbance at 260nm was continuously monitored for solu-
tions of CT-DNA (100μM) in the absence and presence of
the cobalt(III) complex (10μM). The temperature of the so-
lution was increased by 1◦Cmin −1. For the gel electrophore-
sis experiments, super coiled pBR322 DNA (100μM) was
treated with Co(III) complexes in pH = 7.2, and the solu-
tions were incubated for 1 hour h in the dark. The samples
were analyzed by electrophoresis for 2.5 hours at 40V on a
0.8% agarose gel in buﬀer, pH 7.2. The gel was stained with
1μg/ml ethidiumbromide and then photographed under UV
light.
3.4. Spectroscopiccharacterization
Molecular structures of the complexes are given in Figure 1.
The IR spectral data for the complexes are given. The
complexes clearly exhibit a band at 1458cm−1and 1578–
1590cm−1 corresponding to C=Ca n dC =N of the ring, re-
spectively. A band at around 589cm−1 and 590cm−1 cor-
responding to Co−N(en) and Co−No fN H 2(en) bending
exhibits around 1650cm−1. In the 1H-NMR spectra of the
Co(III) complexes, the peaks due to various protons of pyri-
dine shifted downﬁeld compared to the free ligand suggest-
ing complexation. As expected the signal for pyridine ap-
peared in the range between 6.5 to 9.2, CH2 of ethylenedi-
amine gave peaks at 3.1 (br, 4 H, CH2(en)).
3.5. CellviabilityMTTassay
All cell culture reagents and media were purchased from
Sigma-Aldrich and used without further puriﬁcation un-
less otherwise noted. Cytotoxicity assay were performed us-
ing Chinese hamster ovarian (CHO) in order to assess the
cancer chemotherapeutic potential of the cells. Cells were
grown as monolayers in Eagle’s minimum essential medium,
supplemented with 2mM L-glutamine and Earle’s balanced
salt solution, containing 1.5g dm−3, sodium bicarbonate,
0.1mM nonessential amino acids, 1.0mM sodium pyruvate,
100cm−3 penicillin, and 100μgcm−3 streptomycin supple-
mented to contain 10% (v/v) foetal bovine serum. All cells
were grown at 37◦C in a humidiﬁed atmosphere, in the pres-
enceof5%CO2,andwereintheexponentialphaseofgrowth
at the time of assay. Cytotoxicity was assessed using MTT as-
say. Cells (100μL) were seeded at a density of 5 × 104 cells
cm−3 into sterile 96 well ﬂat-bottomed plates (Falcon, Plas-
tics, Becton, Dickinson) and grown in 5% CO2 at 37◦C. Test
compounds were dissolved in culture media. Each drug so-
lution (100μL) was added to replicate wells in the concen-
tration range of 0.1–100μM and incubated for 72 hours.
A miniaturized viability assay using 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was carried
out according to method described by Mosmann [31]. The
IC50 value, deﬁned as the drug concentration causing a 50%
reduction in cellular viability was calculated for each drug.
Each assay was carried out using ﬁve replicates and repeated
on at least three separate occasions. Viability was calculated
as a percentage of solvent-treated control cells, and expressed
as a percentage of the control. The signiﬁcance of any re-
duction in cellular viability was determined using one-way
ANOVA (analysis of variance). A probability of .05 or less
was deemed statistically signiﬁcant.
4. RESULTS AND DISCUSSION
4.1. Absorptionspectralstudies
Absorption titration experiments of Co(III) complexes in
buﬀer were performed by using ﬁxed cobalt complex con-
centration to which increments of the DNA stock solution
were added. The calf thymus DNA was added to a ratio
of 8:1 [DNA]/[Co]. Cobalt solutions were allowed to in-
cubate for 10 minutes before the absorption spectra were
recorded (see Figures 2(a) and 2(b)). As the DNA concen-
tration is increased, the MLTC transition bands of complex
at 618nm exhibit hypochromism and as well as an insignif-
icant bathochromism, showing isosbestic points at 438, 576
and 449, 578 complexes 1 and 2, respectively. Based on the
observations of complexes, we presume that there are some
interactions between complexes and DNA. To know quanti-
tatively the binding strength of the complexes, the intrinsic
binding constant Kb of the complexes with CT-DNA were
obtained by monitoring the changes in absorbance at 618
and 617nm for complexes (1 and 2, resp.) with increasing
concentration of DNA using the following function equation
[32], which has been applied to describe the binding of high-
aﬃnitycomplexestoDNAassumingnoncooperativebinding
to discrete sites:
[DNA]/(a − f) = [DNA]/(b − f)+1 /(K(b − f)),
(1)
where [DNA] is the concentration of DNA in base pairs,
the apparent absorption coeﬃcients a, f and Kb corre-
spondtoAobs/[Co],theextinctioncoeﬃcientforcobaltcom-
plexes in the free and fully bound form, respectively. In plots
[DNA]/(a−f)versus[DNA].K isgivenbytheratioofslope4 Metal-Based Drugs
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Figure 2: Absorption spectra of complexes: (a) complex 1, (b) complex 2, in tris-HCl buﬀer. Upon addition of CT DNA to complex absorp-
tion decreases [Co] = 10μM; [DNA] = 0–126μM. Insert: plots of (a − f)/(b − f) versus [DNA] for the titration of DNA with Co(III)
complexes. Isosbestic points at 438, 576 for complex 1. Isosbestic points at 449, 578 for complex 2.
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Figure 3: Fluorescence emission spectra of complexes: (a) complex 1, (b) complex 2 in tris-HCl buﬀer. Fluorescence intensity increases
upon increasing CT DNA concentrations (5μl, 10μl, 15μl, 20μl, ...). Insert: plots of relative emission intensity versus [DNA]/[Co].
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Figure 4: Fluorescence quenching curves of DNA + complex by ferrocyanide: (a) complex 1 + DNA; (b) complex 2 + DNA.Penumaka Nagababu et al. 5
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Figure 5: Quenching of ﬂuorescence emission of Co(III) complex
+ DNA with Ferro cyanide: (a) complex1 + DNA, (b) complex 2 +
DNA.
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Figure 6: Eﬀect of increasing amount of complexes on the relative
viscositiesofCTDNAat25±0.1
◦:(a )E tB r ,(b)c o mple x2 ,(c )c o m-
plex 1.
to intercept. Intrinsic binding constants K obtained about
2.7 ± 0.2 × 103 and 3.5 ± 0.2 × 103 of complexes 1 and 2,
respectively, from the decay of the absorbance. The binding
constants indicate that complex 2 binds more strongly than
1t oC TD N A .
4.2. Emissionstudies
In the absence of DNA, complexes can emit luminescence
in Tris buﬀer with emission maximum appearing at 562nm.
Upon addition of CT DNA (= Calf thymus DNA), the emis-
sion intensities of the complexes increase when compared
to the intensity of complexes alone shown in Figures 3(a)
and 3(b). This implies that complexes can strongly interact
with DNA and be protected by DNA eﬃciently, since the hy-
drophobicenvironmentinsidetheDNAhelixreducestheac-
cessibility of solvent water molecules to the duplex and the
complexes mobility is restricted at the binding site, lead to
decrease the vibrational modes of relaxation.
This observation is further supported by the ﬂuorescence
quenching experiments using [Fe(CN)6]4− as quencher. The
ion[Fe(CN)6]4− hasbeenshowntobeabletodistinguishdif-
ferentially bound Co(III) species and positively charged free
complex ions should be readily quenched by [Fe(CN)6]4−.
T h ec o m p l e x e sb o u n dt oD N Ac a nb ep r o t e c t e df r o mt h e
quencher, because highly negatively charged [Fe(CN)6]4−
would be repelled by the negative DNA phosphate back-
bone, hindering quenching of the emission of the bound
complex. The method essentially consists of titrating a given
amount of DNA-metal complexes with increasing the con-
centrationof[Fe(CN)6]4− andmeasuringthechangeinﬂuo-
rescence intensity (see Figure 4). The ferro-cyanide quench-
ing curves for these complexes in the presence and absence
of CT DNA are shown in Figure 5. Obviously, complex 2
inserts into DNA much deeper than 1. The absorption and
ﬂuorescence spectroscopy studies determine the binding of
complexes with DNA.
4.3. Viscositystudies
Mode of interaction between the metal complexes and DNA
was clariﬁed by viscosity measurements. Optical photophys-
ical probes are necessary, but not suﬃcient to support a
binding model. Hydrodynamic measurements are sensitive
to length change (i.e., viscosity and sedimentation) are re-
garded as the least ambiguous and the most critical tests of
binding in solution in the absence of crystallographic struc-
tural data [33]. A classical intercalation model results in un-
winding of the DNA helix, which would lead to an increase
in viscosity. In contrast, a partial and/or nonclassical inter-
calation of ligand could bend (or kink) the DNA helix, re-
duce its eﬀective length and concomitantly, its viscosity [30].
Eﬀect of the complexes on the viscosity of rod-like DNA is
showninFigure 6.TheviscosityofDNAisnotincreasedwith
the increase of the concentration of complexes, in contrast to
that of proven DNA intercalator EtBr (= ethidium bromide).
Basedontheviscosityresults,itwasobservedthatthesecom-
plexes bind with DNA through groove binding, result from
DNAmeltingexperimentfurthersupportedtheaboveresult.
4.4. DNAmeltingstudies
As intercalation of the complexes into DNA base pairs causes
stabilization of base stacking and hence raises the melting
temperature of the double-stranded DNA, the DNA melting
experiment is useful in establishing the extent of intercala-
tion [34]. The complexes were incubated with CT DNA and
their temperature raised from 25 to 85◦ and the absorbance
at 260nm was monitored. Conductivity and pH measure-
mentswerealsocarriedoutbeforeandafterheatingthecom-
plexesto85◦ through1hour[35].Thepresenceofmonopha-
sic melting curves with no change in pH. ΔTm values of the
DNA in presence of complexes is shown in Table 1,r e v e a l -
ing avid DNA binding [36]. The complexes show ΔTm val-
ues of 3◦ which is characteristic of a nonintercalative binding6 Metal-Based Drugs
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Figure 7: Plots of A/A0 versus temperature for the melting of CT DNA: (a) 1 only DNA spectra 2 DNA + complex 1, (b) 1 only DNA 2 DNA
+c o m p l e x2 .
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Figure 8: Photocleavage of pBR 322 DNA: lane 1 control plasmid
DNA (untreated pBR 322), lanes 2–11 addition of complex (1) in
amounts of 5, 10, 20, 30...μl. Line 8 at 0 time lanes 7–10, + 5μm
complex up on irradiation (λirrd = 360nm) at 5 minutes, 10 min-
utes, 20 minutes, 30 minutes.
Table 1: ΔTm values of the DNA and complex + DNA.
Compound TM
◦C
CT DNA 60
[Co(en)2(py)2]3+ 63
[Co(en)2(mepy)2]3+ 63
Table 2: IC50 values of complexes 1, 2.
Complexes IC50(nm) Mean±SEM
[Co(en)2(mepy)2]Br3 1.8μM
[Co(en)2(py)2]Br3 1.75μM
behavior (see Figure 7). viscosity experiments further sup-
port the nonintercalative binding.
4.5. PhotocleavageofpBR322DNAbyCo(III)
complexes
TherehasbeenconsiderableinterestinDNAendonucleolytic
cleavagereactionswhichareactivatedbymetalions[37].The
delivery of high concentrations of metal ion to the helix, in
locallygeneratingoxygenorhydroxideradicals,yieldsaneﬃ-
cient DNA cleavage reaction. DNA photocleavage was mon-
itored by relation of supercoiled circular pBR 322 (form I)
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Figure 9: Eﬀects of complex 2 [C], 1[B], and control [A] on the vi-
ability of CHO cells (human hepatocellular), following continuous
incubation for 72 hours, with increasing drug concentration (0.1–
500μM). Bars indicate standard error of the mean (SEM) and re-
sults were statistically signiﬁcant from control at P<. 05. Results
are representative of three independent experiments (n = 3).
into nicked circular (form II) and linear (form III). When
circular plasimd DNA is subjected to electrophoresis, rel-
atively fast migration will be observed for the supercoiled
form (form I). If scission occurs on one strand (nicking),
the supercoils will relax to generate a slower-moving open
circular form (form II) [38]. If both strands are cleaved, a
linear form (III) will be generated that migrates between
f o r m sIa n dI I .Figure 8 shows the gel electrophoretic sep-
arations of plasmid pBR 322 DNA after incubation and ir-
radiation at 360nm with complex 1. This is the result of sin-
glestrandedphotocleavageofpBR322DNA.Thatincubation
with Co(III) without light yields signiﬁcant strand scission.
It is most likely that the reduction of Co(III) is the importantPenumaka Nagababu et al. 7
(a) (b)
Figure 10: The morphological eﬀects exerted by complexes on
CHO cells 24 hours after treatment. Photographs were taken us-
ing a Nikon inverted light microscope (20X objective). (a) shows
the untreated cells and while (b) shows cells treated with 0.5mM of
complex 2.
step leading to DNA cleavage. Further study required to ﬁnd
out the path of reaction mechanism.
4.6. Anticancerstudies
The ability of the cobalt complexes 1 and 2 to kill human-
derived cancer cells was investigated using CHO cells and a
standard bioassay, MTT. Cells were continuously exposed to
test agent for 72 hours, and their eﬀects on cellular viabil-
ity was evaluated. It was intended that the results from these
studies would allow the identiﬁcation of those derivatives
with cancer chemotherapeutic potential. Therefore, proﬁles
of cell viability against complex concentration were estab-
lished Figure 9 and were used to calculate the IC50 values for
each derivative (see Table 2). Comparison of IC50 values al-
lowed the relative potency of each of the test complexes to
be determined and ranked. Photographs of treated and un-
treatedCHOcellsarepresentedinFigure 10.Bothcomplex es
screened displayed a concentration dependent cytotoxic pro-
ﬁle. The order of the observed cytotoxicity was seen as com-
plex 2 appearing as the potent.
5. CONCLUSIONS
In this study, we have attempted to unravel the DNA inter-
action of ethylenediamine pyridine Co(III) complexes. The
binding behavior of complexes with DNA was character-
ized by absorption titration, ﬂuorescence, and ﬂuorescence
quenching and viscosity measurements. The experimental
results indicate that the complexes can bind to DNA through
grooveandCo(III)complexcaneﬃcientlycleavetheplasmid
pBR322. Overall, the results described explain to the DNA-
binding, cleavage ability. The complex containing py ligand
shows better anticancer activity than mepy. The eﬃciency of
these complexes on various cancerous cell lines is presently
being studied in our laboratory.
ABBREVIATIONS
CT DNA: Calf thymus DNA
py: Pyridine
mepy: Methylpyridine
en: ethylenediamine
EtBr: Ethedium bromide
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